The issue of post-marketing surveillance and the reporting or evaluation of adverse reaction is something relatively new, at least to our organization. We're invited here today presumably to give our opinion from the point of view that we come from, but we've never been approached in any direct way to get involved with this.
On February 7th, 2008. See this statement in context.